ENTITY
Ascletis Pharma Inc

Ascletis Pharma Inc (1672 HK)

67
Analysis
Health CareChina
Ascletis Pharma Inc. operates as a biotechnology company. The Company develops and discovers anti-viral drugs to address unmet medical needs in anti-viral, cancer, and fatty liver disease. Ascletis Pharma offers its services worldwide.
more
Refresh
02 Oct 2018 06:08

Last Week in GER Research: Haidilao, Popflops, Bitmain, Shandong Gold, Niu and China Renaissance

Below is a recap of the key IPO research produced by the Global Equity Research team. This week we highlight 25% potential downside at Haidilao as...

Logo
381 Views
Share
28 Sep 2018 09:18

China Renaissance (华兴资本) Trading Update - Trading in Line with CICC

China Renaissance Holdings (1911 HK) raised US$345m at HK$31.80 per share, at the low-end of its range. We covered the IPO in our earlier insight,...

Share
bearishMeituan
24 Sep 2018 06:21

Last Week in GER Research: Meituan, IPO Trading Strategy, Shandong Gold, Maoyan and Viomi

Below is a recap of the key IPO research produced by the Global Equity Research team. This week we highlight that Meituan is closer to fair value...

Logo
327 Views
Share
bearishMeituan
17 Sep 2018 06:37

Last Week in GER Research: Meituan, Nio, Haidilao, Shandong Gold, China Renais., X Financial and PDD

Below is a recap of the key IPO research produced by the Global Equity Research team. This week we dig into the economics of Mobike as it relates...

Logo
357 Views
Share
11 Sep 2018 12:03

Haidilao (6862 HK) IPO: Know When to Say No

Haidilao (6862 HK) announced the price range on Monday morning, coming to market at $10 - $12b through the range.  The nearly $1b dollar range is...

Share
x